ASCO Hematology

Courtney DiNardo, MD, on Looking Forward in AML Treatment
August 05, 2020

The MD Anderson Cancer Center expert discussed the future of acute myeloid leukemia treatment, and how the field is evolving rapidly.

Courtney DiNardo, MD, on Next Steps in Combination Regimens to Treat IDH1-Positive AML
July 30, 2020

The MD Anderson Cancer Center expert discussed next steps in the evaluation of ivosenidib plus venetoclax, with or without azacytidine, in patients with IDH1-mutated acute myeloid leukemia.

Courtney DiNardo, MD, on Combination Regimens Findings in IDH1-Positive AML
July 23, 2020

The MD Anderson Cancer Center expert spoke about the efficacy of ivosenidib plus venetoclax, with or without azacytidine, in patients with IDH1-mutated acute myeloid leukemia.